Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.44 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.44 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | EEF2K | O00418 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7820094 | 0.85 | CHEK1 (0.49) | MAPK1MAP2K4MAPKAPK2MAPK6FGFR1 | |
| SCHEMBL12567890 | 0.82 | ALDH1A1 (0.55) | MAPK1KDR | |
| SCHEMBL8008699 | 0.80 | KMT2A (0.50) | CDK2DYRK1B | |
| SCHEMBL7996516 | 0.78 | RPS6KA3 (0.47) | PDPK1HSP90AB1CHEK1RPS6KA3DYRK1A | |
| SCHEMBL7814496 | 0.78 | FGFR1 (0.41) | PDPK1HSP90AB1MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL7820344 | 0.76 | PDPK1 (0.40) | PDPK1HSP90AB1MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL5221728 | 0.74 | PDPK1 (0.44) | PDPK1HSP90AB1MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL7820618 | 0.74 | ESR1 (0.41) | PDPK1HSP90AB1MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL30639562 | 0.69 | MAPT (0.46) | PDPK1HSP90AB1MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL8011429 | 0.69 | RPS6KA3 (0.69) | MAPK1FGFR1CHEK1RPS6KA3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39708-E1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1102753-B1 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
| US-6291505-B1 | PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-09-18 | — | — | US | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000019994-A9 | ESTROGEN RECEPTOR LIGANDS | UNIV ILLINOIS (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000019994-A1 | ESTROGEN RECEPTOR LIGANDS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | PDPK1 676/4885HSP90AB1 2530/4885MAPK1 1827/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | PDPK1 676/4885HSP90AB1 2530/4885MAPK1 1827/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | PDPK1 676/4885HSP90AB1 2530/4885MAPK1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.